| Code | CSB-RA010327MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Umikibart, targeting hepatocyte growth factor (HGF). HGF is a pleiotropic cytokine that binds to the MET receptor tyrosine kinase, initiating signaling cascades critical for cell proliferation, survival, motility, and morphogenesis. Under physiological conditions, the HGF/MET pathway plays essential roles in tissue regeneration and embryonic development. However, aberrant HGF/MET signaling has been implicated in tumor growth, metastasis, and angiogenesis across multiple cancer types, including gastric, colorectal, and non-small cell lung cancers. Dysregulation of this pathway is also associated with resistance to targeted cancer therapies.
Umikibart is a therapeutic antibody designed to neutralize HGF, thereby blocking its interaction with the MET receptor and inhibiting downstream oncogenic signaling. This biosimilar antibody provides researchers with a valuable tool for investigating HGF-mediated pathways in cancer biology, exploring mechanisms of therapeutic resistance, and evaluating potential combination treatment strategies in preclinical models. It enables studies examining the role of HGF in tumor microenvironment dynamics and metastatic processes.
There are currently no reviews for this product.